End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
14.13 CNY | -0.77% | -1.60% | -40.66% |
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Its low valuation, with P/E ratio at 8.61 and 6.98 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
- The company appears to be poorly valued given its net asset value.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-40.66% | 1.21B | C+ | ||
-16.90% | 8.25B | B+ | ||
+39.20% | 3.58B | C+ | ||
-39.11% | 2.46B | B- | ||
-8.06% | 2.46B | - | ||
-6.78% | 2.38B | B- | ||
-19.01% | 1.55B | A- | ||
+7.56% | 1.11B | B+ | ||
-14.42% | 1.03B | - | - | |
-16.56% | 878M | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 300244 Stock
- Ratings Dian Diagnostics Group Co.,Ltd.